This inventor holds 2 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Astrazeneca Ab, Ionis Pharmaceuticals, Inc.. Active years: 2024-2026.
Company Filing History:
2 out of 1,531 
1 out of 288 
Years Active: 2024-2026
Title: The Innovations of Daniel Laurent Knerr
Introduction
Daniel Laurent Knerr is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that target specific cellular receptors. His work has implications for various therapeutic applications.
Latest Patents
Daniel Knerr holds a patent for "GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof." This patent describes compounds and methods for targeting cells that express the GLP-1 receptor. The innovation aims to enhance the efficacy of treatments related to metabolic disorders.
Career Highlights
Throughout his career, Daniel has worked with prominent companies in the pharmaceutical industry. He has been associated with AstraZeneca AB and Ionis Pharmaceuticals, Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development projects.
Collaborations
Daniel has collaborated with esteemed colleagues, including Brett P. Monia and Thazha P. Prakash. These partnerships have fostered a collaborative environment that promotes innovation and the advancement of scientific knowledge.
Conclusion
Daniel Laurent Knerr's contributions to biotechnology and his innovative patent demonstrate his commitment to advancing medical science. His work continues to influence the development of targeted therapies for various health conditions.